RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04620733 |
|
Recruitment Status :
Completed
First Posted : November 9, 2020
Last Update Posted : September 29, 2023
|
Sponsor:
CymaBay Therapeutics, Inc.
Information provided by (Responsible Party):
CymaBay Therapeutics, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | August 11, 2023 |
| Actual Study Completion Date : | August 11, 2023 |
| Certification/Extension First Submitted : | September 26, 2023 |